News
Flo appoints new executive and launches privacy and security advisory board
The appointments “showcase the company’s commitment to deploying the most rigorous privacy and security standards”, says Flo
The women’s health app Flo has appointed Sue Khan as its new vice president of privacy and data protection officer following the launch of its privacy and security advisory board.
The company says it has established its new privacy and security advisory board by inviting five top experts across the legal, data security and information technology fields with the aim of elevating the bar for privacy and security practices.
The board members will work in collaboration with the company’s in-house privacy and security team and hope to push the femtech and healthtech industries to innovate, improve and rethink their current approach.
Sue Khan will join Flo as vice president of privacy and data protection after spending four years at the digital-first health provider, Babylon Health.
“I am thrilled to join Flo Health as the company has already set such a high standard of privacy and security excellence with the innovation of Anonymous Mode and the ISO 27001 Certification,” Khan said.
“According to Flo’s recent survey, only 13 per cent of the US women feel that they can effectively protect their data.
“One of my goals is to help women feel informed and in control of their health data. My colleagues and I will create a better future for female health by clearly communicating with our users about data privacy rights in simple terms, so they can confidently use Flo without concern.
“My role is dedicated to protecting our users’ privacy rights and freedoms, and safeguarding their most intimate health data.”
Anna Zeiter, associate general counsel and chief privacy officer at eBay, said: “Health apps are in the midst of a privacy and security reckoning.
“In the US, over 80 per cent of women say they are concerned or somewhat concerned about their personal health data.
“Flo’s privacy and security advisory board’s goal is to continue to set industry leading standards in how we build technology to protect users while still delivering incredible value to them.”
She added: “We are going to build off the momentum of Flo’s Anonymous Mode by focusing on transparency, clarity and the power of choice in Flo’s products and in our conversations around data privacy and security.”
In 2022, Flo became the first female health app to receive the ISO 27001 certification.
Following allegations by the Wall Street Journal suggesting the app was sharing its users’ data with Facebook, the company released Anonymous Mode (AM), to allows users to access the app without name, email address, and technical identifiers from being associated with the health data.
The app says its latest appointments “showcase Flo’s commitment to deploying the most rigorous privacy and security standards” to protect its 50 million monthly active users’ data.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Pregnancy6 days agoFrance urges 29-year-olds to start families now







2 Comments